Introduction {#s1}
============

During the past two decades major advances in deciphering the genetic basis of human disease have resulted in thousands of disorders that are now understood at a genetic level ([@bib50]; [@bib74]). This progress has led to the integration of genomic sequencing in clinical care, especially for the diagnosis of rare genetic disease ([@bib11]; [@bib70]), and clinical sequencing is increasingly offered to patients with known or suspected genetic disorders. In the past few years, large national and international efforts ([@bib69]; [@bib85]; [@bib22]) have emerged to enable patients and health systems to share knowledge of rare genetic disorders and improve genetic testing, resulting in improved healthcare management and outcomes for patients. In parallel, many large regional and national biobank efforts ([@bib27]; [@bib9]; [@bib28]) are underway to enable the broad integration of genomics in health systems for genetic identification of disease ([@bib34]). Such efforts have recently revealed clinically actionable variants ([@bib34]; [@bib39]) and genetic disorders segregating at higher frequencies in general patient populations than previously suspected. The increased promulgation of genomics in health systems represents an opportunity to improve diagnostic sensitivity for more precise therapeutic intervention and better health outcomes ([@bib10]).

Despite this progress, most genetic diseases are still under-diagnosed ([@bib2]) or misdiagnosed ([@bib106]; [@bib97]; [@bib19]). A number of barriers exist for wholesale genetic testing and diagnoses, including incomplete standardized guidelines for interpreting genetic evidence of disease ([@bib5]), variable penetrance or expressivity of phenotype ([@bib56]), and that the causal variant may be missed or mis-assigned during testing ([@bib71]). The latter is a particularly pernicious problem in non-European populations due to systematic biases in large genomic and clinical databases ([@bib87]; [@bib84]). These challenges have led several research groups to attempt to genetically identify disease by examining patient health patterns using data from the Electronic Health Record (EHR) ([@bib44]; [@bib46]). EHRs contain comprehensive information on medical care throughout a patient's life, including medications, medical billing codes, physician notes and generated reports (i.e. pathologic, genetic and radiologic reports). EHRs have been used to clinically characterize well-known genetic disorders, but have been of limited success for the vast cadre of less-characterized or unknown disorders ([@bib14]).

The gold standard of genetic disorder diagnosis involves testing both patient and family members to confirm Mendelian segregation of the suspected underlying pathogenic variant ([@bib25]; [@bib24]; [@bib41]). However, as genomic data becomes more ubiquitous in health systems, it can be used to detect genetic relationships in the absence of known family and pedigree information. Specifically, components of pedigrees can be uncovered within the general population; particularly those that have experienced recent founder effects. Pairs of individuals who are related share genetic homology in the form of long genomic haplotypes. These haplotypes are considered to be identical-by-descent (IBD) if they are inherited from a common ancestor without any intervening recombination. The chance of any two people sharing a tract of their genome IBD decays exponentially, with a \~50% reduction in the chance of sharing per generation. However, when IBD sharing does occur, the length of an IBD segment can remain long even between distantly related individuals. In practice, long tracts of IBD (\>3 cM) can be accurately detected using genetic data between individuals with a common ancestor from the past 4--50 generations ([@bib15]). Detection of IBD haplotypes can allow for the identification of distantly related patients with a genetic disorder driven by a locus inherited from a founding ancestor who brought the disease mutation into a population ([@bib53]; [@bib58]; [@bib51]; [@bib76]; [@bib99]; [@bib93]; [@bib60]; [@bib63]). This is the principle underlying population-scale disease mapping approaches that combine IBD sharing and statistical association to discover novel disease loci, so called IBD-mapping.

By detecting genetic relatedness, as inferred by IBD sharing, we hypothesized that we may be able to detect hereditary forms of disease in an EHR-linked biobank. With over 38000 participants, the Bio*Me* biobank, at the Icahn School of Medicine at Mount Sinai, New York City (NYC), is one of the most diverse cohorts ascertained at a single urban medical center under a uniform study protocol. Participants are largely from the local Upper East Side, Harlem and Bronx communities, and represent broad ancestral, ethnic, cultural, and socioeconomic diversity. We initially focused on adult height, which is easily measurable, stable over the adult life course, and one of the most abundantly recorded clinical parameters in EHRs. Height is known to be highly heritable and polygenic ([@bib102]; [@bib64]), however, extremes of short stature can be caused by rare variants in single genes with large effect sizes ([@bib36]). Although, many genetic syndromes are known to cause short stature, most of the time no definitive etiology underlying short stature is found in patients. Here we used loci associated with elevated genetic relatedness as measured by IBD to map a locus underlying extreme short stature in the Bio*Me* biobank, and linked it to a known, but little characterized, collagen disorder previously thought to be rare. By interrogating a large global diversity panel, we demonstrated that this variant is actually common in Puerto Rican populations. Furthermore, we leveraged the EHR to show significant musculoskeletal disease in both heterozygous and homozygous patients, indicating the disease is not simply a recessive disorder as had previously been thought. Finally, we showed how this work can generate broad insights for sustainable adoption and large-scale dissemination of genomic medicine.

Results {#s2}
=======

Detecting patterns of diversity, founder effects and relatedness in the Bio*Me* biobank from New York City {#s2-1}
----------------------------------------------------------------------------------------------------------

The Bio*Me* biobank comprises a highly diverse cohort, with over 65% of participants self-reporting as Black/African-American or Hispanic/Latino/a, and over 35% born outside mainland US, representing more than 110 countries of origin. First we estimated patterns of direct relatedness in a subset of Bio*Me* participants genotyped on the Illumina OmniExpress array (N = 11212) by detecting pairwise identity-by-state using RELATEAdmix ([@bib77]), a method that accounts for admixture in populations ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We observed that 701 individuals had primary (parent-child, sibling) or secondary (avuncular, grandparental) relationship with another participant in BioMe, and we removed these individuals from all downstream analysis. Next we devised a strategy to divide the diverse Bio*Me* biobank into population groups for downstream analysis. We combined genotype data for Bio*Me* participants (N = 10511) with 26 global populations from the 1000 Genomes Project (1KGP; N = 2504) ([@bib1]) and two additional panels of Native American (N = 43) ([@bib72]) and Ashkenazi Jewish populations (N = 100) (see Methods). Using a common set of 174468 SNPS we performed principal component analysis ([@bib88]) (PCA; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Based on both self-reporting and patterns of genetic diversity observed in Bio*Me* participants, we stratified individuals into four broad population groups. The first group self-reported as European American, but were also genetically identified as Ashkenazi Jewish (AJ; N = 808) as they clustered distinctly with an AJ reference panel and separately from other European ancestry groups in PCA space ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). The other three groups we defined using self-reported race/ethnicity categories, African-American (AA; N = 3080), Hispanic/Latino/a (H/L; N = 5102) and European-Americans with no AJ genetic ancestry (Non-AJ EA; N = 1270) ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). An additional 251 individuals who reported 'Mixed' (N = 89) or 'Other' (N = 162) ethnicity were excluded from further analysis.

To evaluate signatures of distant relatedness Bio*Me* biobank participants, we estimated sharing of genomic tracts IBD \>3 cM between every pair of individuals using the GERMLINE software ([@bib48]). The minimum length of 3 cM was chosen based on reports of elevated type I error in call rates of smaller lengths ([@bib49]; [@bib21]). It is known that population-level rates of distant relatedness are observed to be particularly elevated after population bottlenecks (*i.e.* in founder populations) ([@bib17]). We summed the length of all IBD-tracts shared between a given pair of individuals if they shared more than one tract and examined the distribution of pairwise sharing at a population level. We observed elevated levels of distant relatedness in both the AJ (median summed length of IBD sharing within population = 44.7 cM; 95% C.I. = 44.66--44.82 cM) and HL (16.2 cM; 16.18--16.22 cM) populations, compared to AA (3.77 cM; 3.76--3.77 cM) or non-AJ EA (4.5 cM; 4.45--4.55 cM) populations ([Figure 1A](#fig1){ref-type="fig"}). This is congruent with previous reports of founder effects in both AJ populations ([@bib80]) and in some H/L populations ([@bib78]).

![Distribution of Identity-by-Descent sharing among Bio*Me* populations.\
(**A**) Distribution of the pairwise sum of Identity-by-Descent (IBD) sharing (cM) between four broadly defined Bio*Me* populations, namely; African American (AA), Ashkenazi Jewish (AJ), Hispanic/Latino/a (H/L) and Non-Jewish European American (Non-AJ EA). (**B**) Sub-continental diversity in self-reported H/L participants in Bio*Me.* Afro-Caribbean participants fall between European (red) and African (blue) continental reference panels, Mexican and Central/South American H/L participants fall between European and Native American (green) reference panels, mainland US-born participants reside on either cline. (**C**) The tract length distribution of IBD sharing among Bio*Me* populations, normalized by population size. The y-axis represents the proportion population-level sharing (*x / (N\*(N-1)/2)*), where *x* is the sum of the number of pairwise shared IBD tracts and N is the number of individuals per population. The AJ population exhibits the highest level of population level sharing, followed by Puerto Rican born H/L.](elife-25060-fig1){#fig1}

Hispanic or Latino/a is a broad ethnic label encompassing myriad populations with origins in Northern, Southern or Central America, century-long roots in New York City, and genetic ancestry from Africa, Europe and the Americas. To explore the signature of a founder effect in the Bio*Me* H/L population, we leveraged self-reported and genetic information about sub-continental ancestry. By self-reporting, the H/L participants in Bio*Me* were born in New York City (NYC) (40%), Puerto Rico (24%), Dominican Republic (19%), Central/South America (12%), Mexico (2%) or other Caribbean Island (2%) ([Figure 1B](#fig1){ref-type="fig"}). We examined IBD tract length distributions within H/L sub-continental populations and observed that the founder effect was predominantly driven in the Puerto Rican-born group ([Figure 1C](#fig1){ref-type="fig"}). We assembled a cohort of Puerto Ricans including Bio*Me* participants who were either born in Puerto Rico or, were born in NYC and had 2 parents or 3--4 grand parents who were born in Puerto Rico (N = 1245). Approximately 5086 NYC-born H/L individuals did not have recorded parental or grandparental country-of-origin, therefore we also devised a selection strategy using PCA analysis. We identified Bio*Me* H/L participants on the cline between the African and European reference panels in PCA space coincident with Puerto Rican-born individuals. We excluded those on the same cline with ancestry from the Dominican Republic or another Caribbean Island ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}), and counted the remainder (N = 1571) in the Puerto Rican group. In total, we estimated 2816 H/L in the BioMe discovery cohort were of Puerto Rican ancestry, and focused the downstream analysis on this group as the largest founder population in Bio*Me*.

Detecting a locus shared identical-by-descent underlying extreme short stature in Puerto Ricans {#s2-2}
-----------------------------------------------------------------------------------------------

Next we tested the hypothesis that rare, recessive disease variants may have arisen to appreciable frequency in the Puerto Rican founder population. We linked genomic data to clinical data in the Electronic Health Record (EHR) of the Mount Sinai Health System. We focused on height, a stable and ubiquitous health measure. Clinically, rare instances of growth failure or 'short stature' may be caused by a large heterogeneous group of genetic disorders (i.e. skeletal dysplasias) ([@bib37]). We first extracted measures of height for the Puerto Rican adult population of Bio*Me* (mean age = 55.3, standard deviation (s.d.)=16.1). After making exclusions based on age (\>=18 years old for women, \>=22 years old for men, and \<80 years old in both sexes, 194 individuals in total), mean height measurements (mean height = 5' 8.2', s.d. = 3.2' for men; mean height = 5' 2.8' s.d. = 2.8' for women) were consistent with those reported for Puerto Rican populations in a recent global study on height ([@bib79]). We noted that 56 Puerto Ricans met the clinical definition of short stature ([@bib26]) (range of short stature 5'1'−4'0' in men, and 4'8'−3'8' in women) defined as 2 standard deviations below the population-specific mean for men and women separately ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

To test for recently arisen, recessive variants underlying clinical short stature in Puerto Ricans, we implemented a previously published pipeline for 'IBD mapping' ([@bib58]; [@bib101]) ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We first clustered participants into 'cliques' of 3 or more individuals whom, at a given genomic region, shared overlapping homologous IBD tracts of at least 0.5 cM in length in either a heterozygous or homozygous state. Membership in a clique indicates the sharing of a recent common ancestor at that locus, from which the homologous IBD tract was jointly inherited. Clustering of IBD into cliques in the Puerto Rican population (N = 2816) yielded 1434421 IBD-cliques after quality control filters (see Methods). The site frequency spectrum of IBD-cliques ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) demonstrates an expected exponential distribution of clique sizes (of 3--77 haplotypes), representing a class of rare IBD haplotypic alleles (allelic frequency 0.0005--0.0137). To test whether any cliques of IBD haplotypes were significantly associated with height we performed genome-wide association of height as a continuous trait under a recessive model using PLINKv1.9 ([@bib89]; [@bib20]), including the first five PCA eigenvectors as covariates (see Materials and methods). We restricted analysis to 480 out of 1434421 cliques that contained at least 3 individuals who were homozygous for the shared haplotype. Adjusting for 480 tests (Bonferroni adjusted threshold p\<1×10^−4^) one IBD-clique achieved a genome-wide significant signal at the locus 9q32 (IBD-clique frequency = 0.012; β = −3.78; p\<2.57×10^−11^) ([Figure 2A](#fig2){ref-type="fig"}), spanning a large mapping interval chr9:112 MB-120MB. The clique contains 59 individuals, 56 of whom are heterozygous and 3 are homozygous for the associated IBD haplotype.

![Identity-by-Descent mapping reveals locus associated with short stature.\
(**A**) Identity-By-Descent (IBD) mapping for height in Bio*Me* Puerto Ricans using a recessive model. Analysis was restricted to IBD-cliques where at least three individuals were homozygous. Only one IBD-clique achieved Bonferroni significance (at 9q32). (**B**) Distribution of height among Puerto Rican individuals who carry either 0,1 or 2 copies of the IBD-haplotype reveals a large recessive effect. Homozygous individuals (those carrying 2 copies of the IBD-haplotype) are on average 6--10' shorter than the population mean for Puerto Rican ancestry individuals. (**C**) The minimum shared boundary of the significant IBD-haplotype between the three homozygous individuals (represented by the dashed blue line). The top panel depicts known genes at the 9q32 locus. The minimum shared boundary of the IBD overlaps the gene *COL27A1.*.](elife-25060-fig2){#fig2}

Fine-mapping short stature locus reveals putative link to mendelian syndrome {#s2-3}
----------------------------------------------------------------------------

The three individuals driving the recessive signal, two women and one man, were less than 2.5 s.d. shorter (height reduction range 6'−10') than the population mean for height in the Puerto Rican cohort ([Figure 2B](#fig2){ref-type="fig"}). The IBD-haplotypes driving the signal spanned a genic region with several candidate loci, and the minimum shared boundary overlapped a single gene, *COL27A1,* which encodes for Collagen Type XXVII, Alpha 1 ([Figure 2C](#fig2){ref-type="fig"}). We performed whole genome sequencing (WGS) of the three homozygous individuals, and an additional short-statured individual that we observed to possess a homozygous IBD haplotype that was both directly upstream of and highly correlated with the top IBD-clique. Individuals were sequenced to a depth of 4-18X coverage ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Examination of variants that were observed in at least 6 copies between the four individuals (to account for sequencing error or missing calls) revealed a single candidate coding allele, a missense mutation in Collagen Type XXVII, Alpha 1 (*COL27A1*, g.9:*116958257.C\>G,* NM_032888.1, p.G697R, rs140950220) ([Supplemental file 2](#supp2){ref-type="supplementary-material"}). In silico analysis suggest that this glycine residue is highly conserved, and that a molecular alteration to arginine at this position is predicted to be damaging (SIFT score = 0.0; PhyloP score = 2.673; GERP NR score = 5.67). These findings are consistent with a recent report implicating the same *COL27A1* variant as causal for the rare orthopedic condition Steel syndrome in a Puerto Rican family ([@bib43]). First described in 1993, the main clinical features of Steel syndrome include short stature, bilateral hip and radial head dislocations, carpal coalition (fusion of the carpal bones), scoliosis, *pes cavus* (high arches), and dysmorphic features ([@bib95]).

To confirm the link between the IBD haplotype and the putative causal variant, we calculated the concordance between the IBD haplotype and carrier status of the *COL27A1*.pG697R variant by genotyping all of the homozygotes and carriers of the top IBD-clique in the recessive model (N = 59), along with a panel of age- and sex-matched controls (N = 59). This demonstrated 100% concordance between the *COL27A1*.pG697R variant and the significant IBD-haplotype in homozygotes ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). We note that two Puerto Rican participants in the phase 3 1KGP reference panel were carriers of the *COL27A1*.pG697R variant, raising the possibility that we may have been able to detect this association using more a traditional SNP association approach. Therefore, we performed genome-wide association in the same Puerto Rican cohort (N = 2622) by first imputing the 1KGP panel and re-running the recessive test as described above (n = 10007795 imputed and genotyped SNPs with an INFO score of \>0.3 and at least two observations of homozygotes). The recessive model appeared to be well calibrated (λ = 1.02), however, we observed no genome-wide significant signal ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). Association with the *COL27A1*.pG697R variant was the 11775th most significant association (MAF = 0.014: β = −3.0; p\<0.001). Upon examination of the correlation between the imputed *COL27A1*.pG697R and the true carrier status of homozygotes, we noted a concordance of only 66.67%, indicating that the IBD haplotype was a better tag of the true *COL27A1*.pG697R homozygous state compared to 1KGP imputation in the Puerto Rican cohort ([Supplemental file 3](#supp3){ref-type="supplementary-material"}).

The association between *COL27A1*.pG697R and clinical short stature was replicated using a cohort of 1775 individuals of self-reported Puerto Rican ancestry from Bio*Me* that were not included in the discovery analysis, that were genotyped on the Illumina Infinium Multi-Ethnic Genotype Array (MEGA) as part of the Polygeneic Architecture using Genomics and Epidemiology (PAGE) Study. The *COL27A1*.pG697R (rs140950220) variant was directly genotyped on MEGA, and an association of the variant under a recessive model resulted in a strong signal of association (allele frequency = 0.017; β = −3.5; s.e. = 0.70; p\<4.87×10^−07^). The replication analysis revealed 51 additional Bio*Me* carriers and two individuals that were homozygous for the variant. Both carrier and affected status was confirmed *via* independent genotyping and Sanger sequencing (see Materials and methods). The two homozygous participants were both short statured (2.4 and 3.6 s.d from the sex specific population mean).

Evidence from electronic health records supports suspected cases of steel syndrome {#s2-4}
----------------------------------------------------------------------------------

To determine whether there was any clinical evidence to validate the link between the *COL27A1*.pG697R variant and Steel syndrome, a clinical expert manually reviewed the electronic health records (EHR), including clinical diagnoses, surgical procedures, and radiology reports of the five participants (3 women, 2 men, age range 34--74 years) homozygous for the *COL27A1*.pG697R variant that we had identified through the discovery and replication efforts. Of note, there was no evidence that any of the five patients had a clinical diagnosis of Steel syndrome. In all five individuals, however, we found EHR-documented evidence of several previously described Steel syndrome characteristics, including developmental dysplasia of the hip (or congenital hip dysplasia), carpal coalition, scoliosis, and cervical spine anomalies ([Table 1](#table1){ref-type="table"}) ([@bib95]; [@bib40]). The incidence of cervical spine anomalies, including cord compression and spine surgeries, was higher than previously reported (four out of five patients). There was also evidence of other significant musculoskeletal complications, including lumbar and thoracic spine anomalies in three patients, knee replacements in two patients (both under age 50), and joint degeneration or arthritis in four patients. Together, these data help further our understanding of Steel syndrome-associated characteristics and potential complications that can occur later in life.

10.7554/eLife.25060.016

###### Clinical characteristics of five BioMe participants homozygote, thirty-four carriers and thirty-one non-carriers of the *COL27A1*.pG697R variant using evidence documented in Electronic Health Records (including billing and procedural codes, laboratory, radiologic, and progress notes) compared to features previously reported in [@bib40], and [@bib95] for 27 children and 7 adults with Steel syndrome.

  **Characteristics**               **EHR-Documented evidence**          **LiteratureHomozygous children**   **LiteratureHomozygous Adults**   **BioMeHomozygousAdults**   **BioMeHeterozygousAdults \<55yoa**   **BioMeControlsAdults \<55yoa**
  --------------------------------- ------------------------------------ ----------------------------------- --------------------------------- --------------------------- ------------------------------------- ---------------------------------
  Sample size (Gender)              N (N of females)                     27 (9)                              7(6)                              5 (3)                       34(20)                                31(23)
  Age                               Mean age (years)                     12.8                                35.4                              51.6                        41.8                                  40.6
  **Described Characteristics**     **EHR-Documented Medical History**   **N(%)**                            **N(%)**                          **N(%)**                    **N(%)**                              **N(%)**
  Short Stature                     Height \>= 2 s.d. from pop mean      27 (100)                            7 (100)                           5 (100)                     0 (0)                                 0 (0)
  Bilateral hip dislocation         Congenital hip dislocation                                                                                 4                           0                                     0
                                    Leg length discrepancy                                                                                     1                           0                                     0
                                    Total                                27(100)                             7(100)                            5 (100)                     0 (0)                                 0 (0)
  Radial head dislocation           Elbow contractures                   24 (89)                             7 (100)                           1 (20)                      0 (0)                                 0 (0)
  Carpal coalition                  Wrist deformity                                                                                            1                           2                                     1
                                    Lunotriquetial fusion                                                                                      1                           0                                     0
                                    Carpel tunnel                                                                                              0                           3                                     3
                                    Total                                24 (89)                             6 (86)                            2 (40)                      5(15)                                 4(13)
  Scoliosis                         Scoliosis                            12 (44)                             6 (86)                            2 (40)                      8 (24)                                4 (13)
  Pes cavus                         Pes cavus                            12 (44)                             0 (0)                             0 (0)                       0 (0)                                 0 (0)
  Cervical spine anomalies          Cervical stenosis                                                                                          3                           5                                     0
                                    Cervical discitis                                                                                          1                           0                                     0
                                    Cervical spondylosis                                                                                       2                           7                                     3
                                    Cervical cord compression                                                                                  3                           3                                     1
                                    Total                                3 (9)                               0 (0)                             4 (80)                      7 (21)                                3 (10)
  **Other Characteristics**         **EHR-Documented Medical History**                                                                         **N(%)**                    **N(%)**                              **N(%)**
  Other spine anomalies             Lumbar spine                         \-                                  \-                                1 (20)                      10 (29)                               5 (16)
                                    Thoracic spine                       \-                                  \-                                1 (20)                      5(15)                                 4(13)
  Other skeletal disease            Osteoporosis or osteopenia           \-                                  \-                                3 (60)                      3(9)                                  1 (3)
                                    Arthritis or degenerative changes    \-                                  \-                                3 (60)                      13(38)                                6 (19)
  Relevant surgical Interventions   Hip replacement                      \-                                  \-                                3 (60)                      0 (0)                                 0 (0)
                                    Knee replacement                     \-                                  \-                                2 (40)                      0 (0)                                 0 (0)
                                    Cervical spine                       \-                                  \-                                3 (60)                      2 (6)                                 1 (3)
                                    Lumbar spine                         \-                                  \-                                1 (20)                      1 (3)                                 0 (0)
                                    Thoracic spine                       \-                                  \-                                2 (40)                      1 (3)                                 1 (3)

Functional Investigation of *COL27A1.pG697R* {#s2-5}
--------------------------------------------

To understand the biological mechanism underlying Steel syndrome, we investigated the functional role of the *COL27A1* gene. *COL27A1* is a fibrillar collagen, which are a class of collagens that contribute to the structural integrity of the extracellular matrix ([@bib82]). Enrichment of *COL27A1* RNA expression in vertebrae, as well as long bones, eyes, and lungs has previously been observed in embryonic mice ([@bib82]). A mouse deletion of 87 amino acids of the *COL27A1* homolog exhibited severe chondroplasia consistent with clinical features observed in homozygotes ([@bib86]), a similar musculoskeletal phenotype was observed in knockdown of the *col27a1a* and *col27a1b* genes in zebrafish ([@bib23]). Type alpha-1 collagen genes, of which *COL27A1* is a member, contain a conserved Gly-Xaa-Yaa repeat in their triple helical domain ([@bib83]). Therefore, we hypothesized that the *COL27A1*.pG697R variant may similarly disrupt stability of the *COL27A1* triple helix.

To test this hypothesis we modeled the effect of a glycine-to-arginine substitution in the structure of a prototypical collagen peptide ([@bib13]). We observed that the glycine residues occupied the center of the crowded triple helix, and that substitution for a bulkier arginine would likely destabilize helix formation through steric hindrance ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). These data provide support for a functional model of the pathogenicity of *COL27A1.*G697R through destabilization of the triple helix, which may occur within developing spinal chords, long bones, and other tissues, resulting in the observed clinical features in homozygotes. We note that many other collagen disorders, including Ehlers-Danlos syndrome ([@bib75]; [@bib100]; [@bib6]), Alport syndrome ([@bib59]; [@bib107]) and Osteogenesis Imperfecta ([@bib94]; [@bib92]), are driven by molecular alterations of a glycine in the triple helix of the underlying collagen genes. However, all of these disorders are inherited under an autosomal dominant mode, in contrast to Steel syndrome, which has only been reported as a recessive disease. This analysis raises the question of whether some and/or milder clinical features of Steel syndrome may be present in carriers.

Assessing the health records of COL27A1.pG697R carriers reveals evidence of musculoskeletal disease {#s2-6}
---------------------------------------------------------------------------------------------------

To test for clinical features of Steel syndrome in *COL27A1*.pG697R carriers, we performed two analyses using EHR data. The first was a test for associated medical billing codes (ICD9s) with *COL27A1*.pG697R carrier status, or Phenome-Wide Association Study (PheWAS) ([@bib33]; [@bib32]). PheWAS analysis is often performed using a general linear model (GLM), however standard implementations often do not account for scenarios where there is a large imbalance between per-test number of cases and controls, rare variants/ICD9s or the presence of elevated distant relatedness. Therefore, in addition to the GLM, we also ran three other score based tests; (i) that use saddlepoint approximation (SPATest) ([@bib35]) to account for case:control imbalance; (ii) a linear mixed model (GCTA) ([@bib105]) to account for distant relatedness; and (iii) a test that incorporates a bias-reduction for small numbers of observations (Firth test) ([@bib104]). Each test was run using ICD9 codes in all individuals of Puerto Rican ancestry (N = 106 *COL27A1.*pG697R carriers and N = 4480 non-carriers). The five homozygotes were excluded. The ICD9 code was set as the outcome variable and *COL27A1*.pG697R as the primary predictor variable, including age, sex and the first five PCAs as covariates in all tests. To avoid spurious associations, we restricted the analysis to diagnosis codes with at least 3 observations (n = 367 ICD9 codes) amongst carriers.

Results of the GLM test are shown in [Figure 3](#fig3){ref-type="fig"} and [Table 2](#table2){ref-type="table"}. Of the five significantly associated ICD9 codes (False Discovery Rate (FDR) \< 0.05), three involved the musculoskeletal system 730.08 (p~GLM~ \< 7.1 × 10^−6^; odds ratio (OR) = 34.5; 95% Confidence Interval (CI) = 7.4--162), 721.0 (p~GLM~ \< 6.6 × 10^−5^; OR = 5.4; CI = 2.4--12.3), and 716.98 (p~GLM~ \< 4.4 × 10^−4^; OR = 5.8; CI = 2.2--15.3). ICD9 730.08 encodes for 'acute osteomyelitis, other specified sites'. Manual review of chart records for these patients revealed that this code referred to vertebral osteomyelitis in the three carriers with the ICD9 code. ICD9 721.0 encodes for cervical spondylosis without myelopathy. Cervical spondylosis refers to degenerative changes of the cervical spine, which can eventually progress to encroach on the cervical canal, causing myelopathy (spinal cord injury). A third diagnosis code, 716.98, encodes for 'arthropathy, unspecified, or involving other specified sites'. Manual review of chart records for these patients revealed that this code referred to knee arthropathy in all four patients. Finally, two other ICD9 codes were significantly associated with the *COL27A1*.pG697R variant; 622.10 (p~GLM~ \< 1 × 10^−4^; OR = 5.4; CI = 2.3--12.6), which encodes for cervical dysplasia, and 789.1 (p~GLM~ \< 2.1 × 10^−4^; OR = 11.6; CI = 3.2--42.2), which encodes for hepatomegaly. Presently, it is unclear whether these two are related to a *COL27A1*.pG697R carrier phenotype, or are spurious associations.

![Phenome-Wide Association Study (PheWAS) of *COL27A1*.pG697R carriers vs ICD9 billing codes derived from the Electronic Health Records (EHR) under a general linear model (GLM).\
Five billing codes achieve significance (FDR adjusted p\<0.05). Three of the five significant ICD9 codes are in category of musculoskeletal disorders.](elife-25060-fig3){#fig3}
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###### Top five significantly PheWAS associated ICD9 codes in *COL27A1*.pG697R carriers (N = 106) compared to non-carriers (N = 4480).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease category   ICD9 code   \                                                            Number of diagnoses among carriers\   Number of diagnoses among non-carriers\   Odds ratio\                 P-value
                                 Short description                                            N (%)                                 N (%)                                     (5% confidence intervals)   
  ------------------ ----------- ------------------------------------------------------------ ------------------------------------- ----------------------------------------- --------------------------- -------------
  Neoplasms          622.10      Dysplasia of cervix, not otherwise specified                 6 (5.7)                               62 (1.4)                                  5.4 (2.3--12.6)             1.0 × 10--4

  Musculoskeletal    716.98      Arthropathy unspecified, involving other unspecified sites   4 (3.8)                               48 (1.1)                                  5.8 (2.2--15.3)             4.4 × 10--4

  Musculoskeletal    721.00      Cervical spondylosis without myelopathy                      5 (4.5)                               74 (1.6)                                  5.4 (2.4--12.3)             6.6 × 10--5

  Musculoskeletal    730.08      Acute osteomyelitis involving other specified sites          3 (2.8)                               6 (0.1)                                   34.5 (7.4--162)             7.1 × 10--6

  Digestive          789.10      Hepatomegaly                                                 3 (2.8)                               17 (0.4)                                  11.6 (3.2--42.2)            2.1 × 10--4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We observed over inflation in the distribution of the PheWAS test statistic, measured by lambda (λ), for all four score based models (λ~GLM~=1.59; λ~SPATest~=1.20; λ~GCTA~=1.36; λ~Firth~=2.09), indicating that no single model fully accounts for the confounding effects of distant relatedness, case:control imbalance and rare variants/ICD9s ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The code linked to vertebral osteomyelitis (730.08) was the top signal in all tests (p~SPATest~ \< 1.4 × 10^−4^; p~GCTA~ \< 7.9 × 10^−10^; p~Firth~ \< 1.5 × 10^−9^), but only remains significant after genomic control adjustment in one of the tests (p~GCTA_adjusted~ \< 4.6 x 10^−5^). Neither codes linked to cervical spondylosis (721.0; p~SPATest~ \< 3.0 × 10^−3^ (rank=3^rd^); p~GCTA~ \< 3.3 × 10^−3^ (8th)) or knee arthropathy (716.98; p~SPATest~ \< 0.022 (21st); p~GCTA~ \< 3.5 × 10^−3^ (9th); p~Firth~ \< 0.001 (35th))) were significant after genomic control correction. Therefore, while PheWAS analysis provided preliminary support of Steel syndrome-associated clinical features in carriers, best practices for PheWAS models for rare variants/ICD9 codes, and in the presence of population structure, remains an open problem for the genomics community. It is also possible that some relevant clinical features of Steel syndrome might be poorly captured by or absent from medical billing codes.

To evaluate the preliminary evidence from the PheWAS analysis, we performed a second analysis of EHR data that focused on a comprehensive manual chart review to examine for evidence of Steel syndrome characteristics in the *COL27A1*.pG697R carriers in the same manner as performed for homozygotes. We limited the analysis to carriers below the age of 55 (N = 34; mean age 41.8 years) to reduce confounding from age-related related symptoms of spine and joint pain. We also selected 31 age and sex matched Puerto Rican non-carriers for comparison (mean age 40.6 years). Utilizing the same criteria used to characterize Steel syndrome cases, we found no evidence of clinical short stature or hip dislocation in carriers, but did observe a trend of elevated rates of major joint and spine degradation ([Table 1](#table1){ref-type="table"}). In general, 38% (13/34) of carriers showed evidence of spine degeneration varied from severe (multiple level cord compression and neurological symptoms necessitating corrective surgery) to moderate (lower back pain with no neurological symptoms managed with physical therapy and/or pain medication) compared to 13% (4/31) of non-carriers (Fishers exact test p\<0.03). Specifically, we found an increased risk of cervical stenosis in 15% (5/34) of carriers compared to 0% (0/31) of controls (p\<0.05). Although not reaching statistically significance, we show a trend of 2-fold higher rates of scoliosis (24%; p\<0.35), arthritis (38%; p\<0.1), and lumbar spine degradation (29%; p\<0.25) in carriers compared to non-carriers and previous published reports in similar age groups ([@bib57]; [@bib90]). Together these data suggest an appreciable burden of joint and spine degradation in *COL27A1*.pG697R carriers ([Table 1](#table1){ref-type="table"}).

Worldwide frequency and demographic history of COL27A1.pG69R {#s2-7}
------------------------------------------------------------

Having genetically identified and clinically characterized a previously little-known disease variant, we next investigated which populations were at risk for harboring the allele. We assessed the carrier frequencies of the *COL27A1*.pG697R variant in global panel of 51745 individuals from Africa (N = 376), the Americas (N = 45685), Asia (N = 5311), Europe (N = 209), the Middle East (N = 163) and Oceania (N = 28) genotyped on MEGA in the PAGE Study. This included; 13050 in the Multi-Ethnic Cohort (MEC) ([@bib61]) Study; 12327 in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) ([@bib66]); 12852 in the Women's Health Initiative (WHI) Study ([@bib98]); 13044 additional Bio*Me* biobank participants (including the 1775 Puerto Ricans on MEGA described above); and a Global Reference Panel from Stanford University including the Human Genome Diversity Panel ([@bib18]) (N = 986, see Materials and methods). Combined, the PAGE and Bio*Me* dataset represented 57316 individuals from 112 global populations ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). The *COL27A1*.pG697R C allele was present in 183 copies (173 heterozygous carriers and 5 homozygous cases). We estimate the carrier rate of *COL27A1*.G697R to be 1:51 in Puerto Rican-born individuals (minor allele frequency (MAF) = 1.1%); 1:9 in individuals born on the island of St. Thomas (MAF = 11%); 1:346 in Hispanic/Latino/as in the US (MAF = 0.29%) and 1:72 in Bio*Me* Hispanic/Latino/a populations from New York City (MAF = 0.7%); and 1:746 in individuals born in the Dominican Republic (MAF = 0.067%) ([Figure 4A](#fig4){ref-type="fig"}). We note that only 9 people were assayed from St. Thomas, so the high carrier frequency estimate could be biased by small sample size. Finally, the variant is present in only 4 copies in the 60,706 exomes in the ExAC database ([@bib38]), likely due to differences in the populations comprising both datasets.

![Allele frequency distribution and demographic history of *COL27A1*.pG697R. \
(**A**) Global carrier frequency of *COL27A1*.pG697R in a multi-ethnic database of over 57,000 individuals representing 112 populations. The variant is absent or very rare in most populations (purple), at 1:746 and 1:346 carrier frequency amongst individuals from the Dominican Republic and Hispanic/Latino/as in the United States (green), and at 1:51 and 1:9 carrier frequency amongst individuals from Puerto Rico and St. Thomas (yellow). (**B**) Joint analysis of identity-by-descent and local ancestry haplotypes in three individuals homozygous for the *COL27A1*.pG697R variant. A large 15 cM interval on chromosome 9 is shown with local ancestry inferred as African (blue), European (red) and Native American (green), with shading to indicating the boundaries of the IBD haplotypes. The location of *COL27A1* is indicated by the dashed line (**C**) Effective population size of the Puerto Rican discovery population (N = 2816) over the past 4--25 generations inferred from the tract length distribution of IBD haplotypes suggests that the ancestral population underwent a bottleneck approximately 9--14 generations ago. 95% confidence intervals are represented by blue ribbon.](elife-25060-fig4){#fig4}

To predict what other populations might be at risk for Steel syndrome, we explored the locus-specific demographic history in carriers of the *COL27A1*.pG697R risk haplotype. First, by visual inspection, we were able to discriminate a single haplotype of 107.5 kb in length that contained 55 SNPs, which uniquely tagged the *COL27A1*.pG697R variant (R^2^ = 1). This haplotype was present only in individuals born in Puerto Rico (N = 25), the Dominican Republic, (N = 2), Columbia (N = 1), New York City (N = 40) and St. Thomas (N = 1). Genotyping determined that only the haplotype carriers from Puerto Rico, New York City and St. Thomas also carried the *COL27A1*.pG697R variant (N = 56 in total). Second, we inferred continental ancestry along the genomes of the three Puerto Rican homozygotes in the discovery cohort. Local ancestry inference is the task of assigning continental ancestry to genomic segments in an individual with recent ancestors from multiple continents. For the Puerto Rican homozygotes, we estimated local haplotypic similarity with a reference panel of African, European and Native American genomes using RFMix ([@bib73]). Examination of local ancestry on the background of the IBD haplotype in all three homozygous individuals revealed all to be homozygous for Native American ancestry, suggesting the *COL27A1*.pG697R arose on a Native American haplotype ([Figure 4B](#fig4){ref-type="fig"}).

To test whether the disease variant arose via genetic drift or selection, we used the IBDNe software ([@bib16]) to estimate the historical effective population size (N~e~) of the Puerto Rican discovery cohort (N = 2816) ([Figure 4C](#fig4){ref-type="fig"}). The IBDNe software calculates the effective population size of a given population over past generations by modeling the distribution of IBD tract lengths present in the contemporary population. The analysis suggested evidence of a strong bottleneck in Puerto Ricans approximately 9--14 generations ago, with the smallest effective population sized dating approximately 12 generations ago (estimated N~e~ = 2580, 95% C.I 2320--2910). This is consistent with the timing of European immigration and slave trading on the Island, resulting in admixture and population bottlenecking, followed by demographic growth post-contact ([@bib78]; [@bib45]). Finally, to see if there was evidence that the locus had undergone a recent selective sweep we calculated the integrated haplotype score (iHS) ([@bib103]; [@bib96]) across chromosome 9 in phased genotype data for Bio*Me* Puerto Rican samples, but did not observe evidence of selection at the locus ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Together, this evidence suggests that the *COL27A1*.pG697R variant arose in the ancestral Native American populations that peopled the Caribbean, which underwent a strong bottleneck during the period of colonization, which may help explain the prevalence of this disease in amongst contemporary Puerto Rican populations.

Discussion {#s3}
==========

Here we describe a new approach to utilize genomic data in health systems for identifying and characterizing genetic disorders, the cornerstone of which is the ability to identify related individuals in the absence of recorded pedigree or genealogy information. By linking medical records of distantly related patients, identified by shared tracts of genetic homology identical-by-descent (IBD), we discovered a recessive haplotype on 9q32 conferring extreme short stature. Whole genome sequencing revealed that a mutation (Gly697Arg) in the *COL27A1* gene had been previously implicated as the genetic variant underlying Steel syndrome ([@bib43]; [@bib95]; [@bib40]). Population screening indicated that the disease variant is more common than previously thought in people with Puerto Rican ancestry, and in some other Caribbean populations, and very rare or absent elsewhere in the world. Extensive analysis of clinical records confirms almost all features of the recessive disorder in cases, and reveals potential complications that can occur later in life. An agnostic survey of the medical records of carriers, supplemented by manual chart review, indicates evidence of joint and spine degradation in heterozygotes. Biochemical modeling suggests that *COL27A1.*G697R disrupts a conserved triple helix domain of the alpha-1 collagen in a mechanism similar to dominant forms of other collagen disorders ([@bib83]). Taken together, this study indicates that a single mutation in the *COL27A1* gene underlies a common collagen disorder impacting up to 2% of people of Puerto Rican ancestry.

This is consistent with our finding, supported by previous work ([@bib78]), demonstrating a founder effect in Puerto Rican populations. Despite segregating at an estimated carrier rate of 1:51, the *COL27A1.pG697R* variant was first described very recently ([@bib43]). This suggests that there may be other highly penetrant disease variants segregating at appreciable frequencies in Puerto Rican populations ([@bib7]; [@bib29]; [@bib30]; [@bib3]; [@bib8]; [@bib67]), and other understudied founder populations, the discovery of which could lead to new disease variants and biology. Indeed, although *COL27A1* was first implicated as the Steel syndrome disease locus in an extended family from Puerto Rico recently ([@bib20]), other variants in *COL27A1* have since been linked to Steel syndrome in Indian ([@bib62]) and Emerati ([@bib42]) families revealing additional clinical features of the disease such as hearing loss. In our own health system, approximately 190,000 patients of Puerto Rican descent are treated annually ([@bib55]). We estimate that up to 80 may have the severe homozygous form of the disorder and that the milder heterozygous form could be found in up to 1200 patients. A search of progress notes, discharge summaries, and operative reports of over 4 million patients in the Mount Sinai data warehouse discovered mentions of the text term 'Steel Syndrome' in 42 patient records. However, all of these patients were on dialysis for end stage renal disease, indicating that this mention was a misspelling of vascular Steal Syndrome, which is common in dialysis patients. This suggests that Steel syndrome might be largely undiagnosed. Attempts are currently being made to re-contact Bio*Me* participants with suspected Steel syndrome, and a genetic test is now available at Mount Sinai (website: <http://sema4genomics.com/products/test-catalog/>).

This study highlights the benefits of incorporating statistical and population genetics approaches in medical genetic research. First, we demonstrated that leveraging distant relationships *via* IBD mapping was better powered for discovery of the *COL27A1* variant compared to a more typical GWAS approach (i.e. genotype, imputation, and SNP association). As sample sizes increase in health systems and biobanks, the odds of a new individual being a direct or distant relative of someone already in the database increases exponentially ([@bib52]), enabling the detection of shared haplotypes harboring rarer causal variants and better-powered IBD mapping studies. Second, we inferred that *COL27A1*.pG697R variant arose on a Native American haplotype, and we estimate that the allele may have segregated at a carrier frequency of 25--30% in pre-Columbian Taíno populations and/or been driven to its current frequency by a bottleneck that occurred during the early days of colonization in Puerto Rico. Therefore this study not only helps estimate population attributable risk of *COL27A1*.pG697R in Puerto Rican populations, but also to predict other populations potentially at risk, including other Caribbean and Taíno populations. Targeted population screening of *COL27A1*.pG697R could potentially provide personalized health management, surveillance for associated complications, guidelines for intervention (particularly in newborns \[[@bib40]\]), and improved reproductive choices.

This work also highlights some of the current challenges in the emerging field of genomic medicine. We demonstrated that evidence from EHRs could be readily extracted and retrospectively used to characterize clinical features of a musculoskeletal genetic disorder. However, features of many other genetic disorders may not be detectable via routine clinical exam, lab tests and radiologics, and may not be amenable to such an approach. Furthermore, statistical methods for population-scale disease variant discovery, which were predominantly developed for cohorts collected for genetic research, may not be optimally calibrated for discovery in patient populations encountered in health systems. Finally, many genetic disorders are very rare, or have more complex genetic underpinnings, which would reduce power for detection using the strategy we have described. However, recent efforts, such as the Precision Medicine Initiative, that focus on the broad adoption of genomics in medicine, combined with international efforts to catalog rare genetic diseases, are primed to increase the rate of incidental genetic diagnosis of disease.

In summary, this work demonstrates the utility of biobanks for exploring full medical phenomes, and highlights the importance of documenting a wider spectrum of genetic disorders, in large and diverse populations of humans. In particular, this method provides a bridge between classical medical genetic methods and those employed in population-level GWAS. Here we note that the *COL27A1* variant is very rare in current large-scale genomic databases used for clinical research. Thus traditional association strategies and ascertainment bias focused on populations of European descent would have failed to identify and characterize this disorder and its public health burden. As ours and other recent studies have demonstrated, EHR-embedded research will be increasingly important for disentangling the pathology of rare genetic disorders, and understanding the continuum of complex and Mendelian disease. As studies grow in size, and healthcare systems learn to leverage the wealth of information captured in the EHR, there is a need to provide relevant medical information to any patient entering the clinic anywhere in the world. Methods like that described here allow for precision medicine with a truly global outlook.

Materials and methods {#s4}
=====================

BioMe biobank program {#s4-1}
---------------------

Study participants were recruited from the Bio*Me* Biobank Program of The Charles Bronfman Institute for Personalized Medicine at Mount Sinai Medical Center from 2007 onward. The Bio*Me* Biobank Program (Institutional Review Board 07--0529) operates under a Mount Sinai Institutional Review Board-approved research protocol. All study participants provided written informed consent. Of the approximately 38000 participants currently enrolled in Bio*Me,* N = 10511 unrelated are genotyped on the Illumina Infinium OmniExpress (OMNI) array. 5102 of these participants self-report as 'Hispanic or Latino/a', 3080 as 'African American or African', 2078 as 'White or Caucasian', 89 as 'Mixed' and 162 as 'Other'. Country of origin information is available for all but N = 5 participants, with N = 6553 reporting being born in the United States and the remaining N = 3953 report being born outside of the US. Parental and grandparental country of origin information is only available for a small subset of individuals genotyped on the OMNI array (N = 43). An additional N = 10471 participants were genotyped on the Illumina Infinium Multi Ethnic Genotyping array (MEGA) v1.0. Of these, approximately 4704 self-reported 'Hispanic or Latino/a' ethnicity, 3143 self-reported as 'African American or African', 22 self-reported as 'White/Caucasian', 708 self-reported as 'Mixed' and 1894 self-reported as 'Other'. Country of birth information was available for all but a small number of participants (N = 228), with 5190 reporting being born in the United States, and the remaining 5053 self-reporting being born elsewhere. Parental and grandparental country of origin information is available for 4323 individuals genotyped on the MEGA array.

OmniExpress genotyping and QC {#s4-2}
-----------------------------

Genotyping of 12749 Bio*Me* participants was performed on the Illumina Infinium OmniExpress plus HumanExome array. Calling was performed using the GenomeStudio software. A total of 1093 individuals were removed prior to zCall due to plate failure (N = 672), unambiguous discordance between genetic and EHR recorded sex (N = 693), a call rate of \<98% (N = 834), or deviances in levels of heterozygosity (N = 773 in total). This was defined as having either an inbreeding coefficient outside the range −0.1 and 0.3 for common alleles (MAF \>1%), or between 0.4 and 0.9 for rare alleles (MAF \<1%). Additional quality control of 11656 individuals was performed using PLINK1.7 ([@bib89]) (RRID:[SCR_001757](https://scicrunch.org/resolver/SCR_001757)). An individual with a call rate of \<99% was also excluded (N = 1), along with intentional genetic duplicates (PiHat \>0.8, N = 444). Site-level quality control consisted of the removal of SNPs with a call rate of \<95% (n = 42217), and the removal of sites that were significantly out of Hardy-Weinberg equilibrium (p\<1×10^−5^; n = 39660) when calculated for self-reported EA, AA and H/L separately. Palindromic sites and those that deviated considerably from the 1KGP allele frequencies (\<40% *versus *\>60%) were also removed to ensure uniform stranding across datasets. After QC steps, 11212 participants and 866864 SNPs remained for downstream analysis.

IBS relatedness estimates and estimation of inbreeding Co-efficient {#s4-3}
-------------------------------------------------------------------

Pairwise IBS-based relationship estimates were derived for Bio*Me* participants (N = 11212) using the RELATEAdmix software ([@bib77]), which accounts for inflation of IBS statistic due to admixture linkage disequillibrium in admixed populations. To include allele frequency information and global ancestry proportions from ancestral populations relevant for each admixed population in the analysis. These were estimated using ADMIXTURE ([@bib4]) (RRID:[SCR_001263](https://scicrunch.org/resolver/SCR_001263)) H/L samples were merged with the Utah Residents (CEPH) with Northern and Western European Ancestry (CEU; N = 100), Yoruba in Ibadan, Nigeria (YRI; N = 100) and Native American (NA; N = 43; including Nauha, Ayamaran, Mayan and Quechan individuals) and used as input for the ADMIXTURE software, which was run unsupervised at k = 3. ADMIXTURE analysis confirmed that NA reference panel comprised \>99% proportion Native American genetic ancestry ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). European-American (EA) individuals were merged with the CEU and a panel of self-reported Ashkenazi Jewish individuals genotyped on OMNI from Bio*Me* (AJ; N = 100) and run unsupervised at k = 2. AA samples were merged with the CEU and YRI reference panels and run unsupervised at k = 2. After intersecting with reference panels 99296 SNPs were used as the input for RELATEAdmix.

Principal component analysis {#s4-4}
----------------------------

Principal Component Analysis (PCA) was performed using the SMARTPCAv10210 software from the EIGENSOFTv5.0.1 (RRID:[SCR_004965](https://scicrunch.org/resolver/SCR_004965)) ([@bib88]) in 10511 unrelated Bio*Me* participants. Regions containing the Human Leukocyte Antigen (chr6: 27000000--35000000 (NCBI37/hg19)), Lactase gene (chr2:135000000--137000000 (NCBI37/hg19)) and a common inversion (chr8:6000000--16000000 (NCBI37/hg19)), all of which are regions known to confound PCA analysis were removed from the genotype data prior to analysis. Data were merged with a reference panel of 2504 individuals from Phase 3 of the 1KGP (RRID:[SCR_006828](https://scicrunch.org/resolver/SCR_006828)) ([@bib1]) that was constructed by extracting OmniExpress sites from whole-genome sequence data. Following this, a further two other relevant reference panels were added: the NA (N = 43), and AJ (N = 100) panels described above. A total of 174468 SNPs remained after intersecting the data with these reference panels.

Identity-by-descent tract inference and clustering {#s4-5}
--------------------------------------------------

Phased genotype data were filtered to MAF \>0.01 and converted to PLINK format using the FCGENE software ([@bib91]) (we avoided using PLINK software for the conversion process in order to retain the phase information). Recombination maps from HapMap II (Build GRCh37/hg19) were intersected with the genotyped sites (n = 490510 SNPs). GERMLINE (RRID:[SCR_001720](https://scicrunch.org/resolver/SCR_001720)) ([@bib48]) was used to infer tracts of identity by descent \>3 cM across all pairs of Bio*Me* individuals (N = 11212) using the following flags: *'-min_m 3 -err_hom 0 -err_het 2 -bits 25 --haploid'.* IBD haplotypes that fell within or overlapped with centromeres, telomeres and regions of low complexity were removed from the GERMLINE output using an in-house Ruby script. Additional quality control measures consisted of the exclusion of regions of the genome where the depth of IBD-sharing (that is, the number of pairwise IBD-haplotypes that contain a given locus of the genome) exceeded 4 standard deviations from the genome-wide mean ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}).

IBD clustering to identify 'cliques\' of three or more IBD haplotypes shared between multiple individuals was then performed using the efficient connect-component-based clustering version of the Dash Associated Shared Haplotypes algorithm (DASH) ([@bib47]), using the default parameters. As a further quality control measure IBD-sharing 'cliques' inferred by DASH that exhibited excessive sharing (which we defined as clique membership that exceeded 4 s.d. above the genome-wide mean) were removed ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). Data was outputted from DASH in PLINK tped format, and alleles were encoded as; homozygote member in a clique as '2', heterozygote member as '1' and everyone else not a member in the clique encoded as '0'.

Population-level IBD sharing {#s4-6}
----------------------------

We calculated the length of any pairwise IBD tract (or sum of the lengths if a pair of individuals shared more than one tract IBD) for each IBD sharing pair within each population to obtain an estimate of the mean and variance of pairwise sharing per population. To compare the tract length distribution between populations (of size *N*), we first binned pairwise IBD tracts by length bin in 0.01 cM increments. We then summed the number of pairwise IBD tracts falling into each length bin (*x*), and divided this number by the number of possible pairwise IBD sharing for each population: N\*(N-1)/2.

Height measurement and transformation {#s4-7}
-------------------------------------

A self-reported measurement of height in feet and inches was recorded for each participant at enrollment into the Bio*Me* program. Raw height data were stratified on the basis of sex for all individuals who were inferred to be of Puerto Rican ancestry (N = 2816). Height data was then log transformed and converted to age-adjusted Z-scores. Participants were excluded on the basis of age reported at the point of enrollment, with a minimum cut-off of 18 years old for females (N = 0) and 22 for males (N = 0), and a maximum cut off of 79 years old for both sexes (N = 194) leaving a total of n = 2622 PR.

Association of IBD-cliques with height under a recessive model {#s4-8}
--------------------------------------------------------------

Association of IBD clique membership with height as a continuous trait was performed under a recessive model using PLINKv1.9 ([@bib20]) using the *'\--linear recessive*' flag. Age and sex adjusted Z-scores for height were used as the outcome variable. IBD clique membership was used as the primary predictor variable and the first five PCA eigenvectors were used as covariates. The model was run across a total of 2622 PR ancestry individuals and a total of 480 IBD-cliques where at least 3 individuals were homozygous for the IBD haplotype.

Genome wide association of imputed data under a recessive model {#s4-9}
---------------------------------------------------------------

Genotype data for all of the Bio*Me* individuals ascertained on the Illumina OMNI Express array (N = 11212) were phased together using SHAPEIT2 ([@bib31]; [@bib81]). Imputation was subsequently performed in 5 MB chunks using IMPUTE2 (RRID:[SCR_013055](https://scicrunch.org/resolver/SCR_013055)) ([@bib54])*via* the flags *'-Ne 20000 -buffer 250 -filt_rules_l \'ALL\<0.0002\' \'ALL\>0.9998\'*' with a reference panel derived from phase 3 data from the 1KGP. A total of 46538253 SNPs were imputed from 828109 directly genotyped SNPs.

We ran a recessive GWAS on the same 2622 inferred Puerto Rican ancestry individuals used in our recessive IBD-mapping model. The association was run over hard-called data using the PLINKv1.9 software using the *'\--linear recessive*' flag. Age and sex adjusted Z-scores for height were used as the phenotypic outcome and the first five PC eigenvectors were used as covariates. Analysis was restricted to SNPs with \>= 2 observations of individuals homozygous for the minor allele (as the only 2 of the 3 homozygotes had been imputed correctly), and SNPs with an INFO score of \>= 0.3 (n = 10007795 SNPs in total).

Whole genome sequencing {#s4-10}
-----------------------

Genomic libraries were prepared from DNA obtained for the four IBD homozygous individuals. DNA was sheared to 300 bp on a Covaris E220, libraries were made using the NEBNext Ultra DNA Library Prep kit for Illumina. The libraries were submitted for Whole Genome Sequencing (WGS) at the Mount Sinai Genomic Core using the Illumina HiSeq 2500 system, performed by the Genomics Core Facility of the Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai. Reads were aligned to the NCBI37/hg19 reference genome and variants were called using the sequence analysis pipeline by [@bib68] Variant calls and coverage at every site at the genomic interval spanned by the candidate IBD haplotype (chr9:112000000--118000000 bp (NCBI37/hg19)) were obtained using the *'-out_mode EMIT_ALL_SITES*' flag in GATKv3.2--72 (RRID:[SCR_001876](https://scicrunch.org/resolver/SCR_001876)). For summary statistics of whole genome sequencing (WGS) see [Supplement file 1](#supp1){ref-type="supplementary-material"}.

In silico analysis and validation of COL27A1.pG967R {#s4-11}
---------------------------------------------------

WGS variant calls were annotated with allele frequency information and in silico prediction scores for SIFT, PhyloP, GERP generated using snpEffv3.0 (RRID:[SCR_005191](https://scicrunch.org/resolver/SCR_005191)) as part of the sequence analysis pipeline published by [@bib68]. We identified all genomic variants that were present in at least 6 copies across the four IBD-homozygotes and that lay within the shared boundary of the IBD haplotype. Using this criteria, only one rare, coding variant was found to be shared between all four homozygotes, namely a point mutation in the gene *COL27A1* (g.9:*116958257 .C\>G,* NM_032888.1, p.G697R, rs140950220) which was present in 7 copies (with 3 individuals being homozygous, and the fourth being heterozygous). The rs140950220 G/C allele status was validated by Sanger sequencing of exon 7 in the *COL27A1* gene in all four individuals. We also validated *COL27A1.*pG697R status in individuals carrying the significant IBD-clique at 9q32 using the Fluidigm SNPType assay adhering to the standard protocol. All individuals carrying at least one copy of the top IBD-haplotype (N = 59) were genotyped for the rs140950220 variant in addition to a panel of age and sex matched Puerto Rican ancestry controls (N = 59).

Genotyping COL27A1.pG697R in a Multi-Ethnic population of PAGE {#s4-12}
--------------------------------------------------------------

We estimated the frequency of the *COL27A1.pG697R (*dbSNP = rs140950220) variant in the Population Architecture using Genomics and Epidemiology (PAGE) study. The PAGE study comprises a diverse global reference panel from five studies. African-American and Hispanic/Latina women from the Women's Health Initiative (WHI), a multi-center cohort study investigating post-menopausal women's health in the US and recruited women at 40 centers across the US. Self-identified Hispanic/Latino/as from four sites in San Diego, CA, Chicago, IL, Bronx, NY, and Miami, FL as part of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). African American, Japanese American, and Native Hawaiian participants from the Multiethnic Cohort (MEC) prospective cohort study recruiting men and women from Hawaii and California. The Global Reference Panel (GRP) created by Stanford University contributed samples including; a population sample of Andean individuals primarily of Quechuan/Aymaran ancestry from Puno, Peru; a population sample of Easter Island (Rapa Nui), Chile; individuals of indigenous origin from Oaxaca, Mexico, Honduras, Colombia, the Nama and Khomani KhoeSan populations of the Northern Cape, South Africa; the Human Genome Diversity Panel in collaboration with the Centre Etude Polymorphism Humain (CEPH) in Paris; and the Maasai in Kinyawa, Kenya (MKK) dataset from the International Hapmap Project hosted at Coriell. Finally, the Bio*Me* biobank in the Mount Sinai health system, New York City, contributed African-American, Hispanic/Latino/a, and participants who reported as mixed or other ancestry to the PAGE study,\~50% of whom were born outside New York City and for whom country-of-birth information was available. In all, participants in the PAGE Study represent a global reference panel of 112 populations ranging from 4 to 17773 individuals in size ([Supplement file 4](#supp4){ref-type="supplementary-material"}). Samples in the PAGE study were genotyped on the Illumina Multi-Ethnic Genotyping Array (MEGA), which included direct genotyping of the rs140950220 variant. A total of 53338 PAGE and GRP samples were genotyped on the MEGA array at the Johns Hopkins Center for Inherited Disease Research (CIDR), with 52878 samples successfully passing CIDR's QC process. Genotyping data that passed initial quality control at CIDR were released to the Quality Assurance/Quality Control (QA/QC) analysis team at the University of Washington Genetics Coordinating Center (UWGCC). The UWGCC further cleaned the data according to previously described methods ([@bib65]) and returned genotypes for 51520 subjects. A total of 1705969 SNPs were genotyped on the MEGA. The *COL27A1.*pG697R variant passed the following filters; (1) CIDR technical filters, (2) SNPs with missing call rate \>= 2%, (3) SNPs with more than 6 discordant calls in 988 study duplicates, (4) SNPs with greater than 1 Mendelian errors in 282 trios and 1439 duos, (5) SNPs with a Hardy-Weinberg p\<10^−10^, (6) positional duplicates.

Structural modeling of the COL27A1.PG697R missense variant {#s4-13}
----------------------------------------------------------

We downloaded X-ray crystal coordinates (1CAG from [@bib13].; [www.pdb.org](http://www.pdb.org)) on January 21, 2017. Visualization and modeling of the missense variant were performed in PyMol ([www.pymol.org](http://www.pymol.org); RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)).

Phenome-Wide association study {#s4-14}
------------------------------

To test for clinical symptoms of Steel syndrome in *COL27A1*.pG967R carriers, we performed a Phenome-Wide Association Study (PheWas) with EHR-derived ICD9 billing codes as the phenotypic outcome. In the association model, for each individual ICD9 codes were encoded as '1' if the ICD9 was present in their EHR, and '0' if the ICD9 code was absent. Carrier status for *COL27A1*.pG697R was used as the primary predictor variable, with heterozygous individuals encoded as '1', non-carriers encoded a '0' and homozygotes excluded from the analysis. We restricted the analysis to carriers of *COL27A1*.pG697R (n = 106) and non-carriers (n = 4480) who either reported being born in Puerto Rico or who were US-born, self-identified as H/L and overlapped with Puerto Rican born individuals in principal component analysis. Age, sex and the first 5 principal components were included as covariates in our model. The regression was performed using four methods; Generalized Linear Models (GLM) using the glm() function in Rv3.2.1; a score test based on the saddlepoint approximation (SPATest) using the SPAtest() function in Rv3.2.1; a score test using a base adjustment for rare variants (Firth test) using the logistf() function in Rv3.2.1; and a linear mixed model using the GCTAv1.24.2 software with a genetic relationship matrix constructed from 281666 SNPs shared between the OMNI and MEGA arrays (MAF \>= 1%). To adjust for multiple tests, raw p-values were adjusted for false discovery rate using the p.adjust() function in R, and only those below an FDR adjusted p-value of 0.05 were reported as significant.

Clinical review of patient records {#s4-15}
----------------------------------

Information from inpatient, outpatient, emergency and private practice settings housed in the Mount Sinai health system since 2004 was reviewed by two clinical experts independently. This data includes laboratory reports, radiological data, pathology results, operative and inpatient/outpatient progress notes, discharge summaries, pharmacy, and nurses reports. The clinical experts examined for clinical features similar to those reported for Steel syndrome cases in [@bib40], including developmental dysplasia of the hip (or congenital hip dysplasia), carpal coalition, scoliosis, and joint and spine anomalies. Both clinical experts reviews patient records independently and compared notes to resolve discrepancies. They reviewed the records of the 34 youngest *COL27A1*.pG697R carriers (mean age 42), and compared their findings to 31 randomly selected age and sex matched Puerto Rican non-carriers, and also to published reports of population prevalences of key clinical features for similar age groups where available.

Local ancestry estimation {#s4-16}
-------------------------

Due to the process of recombination, individuals from populations that have undergone recent admixture can exhibit a mosaic of genetic ancestry along their genome. Their genetic ancestry at a given genomic segment (referred to as local ancestry), can be inferred from genotype data with the use of non-admixed reference panels of known continental ancestry. We calculated local ancestry in the three homozygous Puerto Rican individuals genotyped on OMNI by first extracting the intersecting sites of the Affymetrix 6.0 array (n = 593729 SNPs in total) and merging them with 3 ancestral reference panels. These reference panels consisted of the CEU and YRI samples from the 1KGP in addition to the Native American reference panel described previously that were used as a proxy for European, African and Native American ancestral source populations, respectively. RFMix ([@bib73]) was used to infer local ancestry.

Calculation of historical effective population size in Puerto Ricans {#s4-17}
--------------------------------------------------------------------

To investigate evidence of a founder effect in Puerto Ricans we ran the IBDNe software ([@bib16]) in 2816 Puerto Ricans from the discovery effort using the cleaned set of pairwise IBD-haplotypes inferred using GERMLINE. IBDNe was run using the default parameters, including an assumed generation time of 25 years.

Data availability {#s4-18}
-----------------

All scripts used to generate main and supplementary figures for this manuscript are available for download on GitHub (<https://github.com/gillian-belbin/ibdmapping_ehr_figscripts> \[[@bib12]\]; a copy is archived at <https://github.com/elifesciences-publications/ibdmapping_ehr_figscripts>). The data frames of analysis results that were used to generate the main and supplementary figures are located here: <http://research.mssm.edu/kennylab/data_source_file.tar.gz>

Web resources {#s4-19}
-------------

BioMe OmniExpress data: <https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000888.v1.p1>

BioMe MEGA data: <https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000925>

PAGE MEGA data: <https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356>

*Location of Native American panels:* <ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130711_native_american_admix_train/>

Software used in the analysis:

SMARTPCA: <https://github.com/DReichLab/EIG>

ADMIXTURE: <https://www.genetics.ucla.edu/software/admixture/download.html>

RelateAdmix: <http://www.popgen.dk/software/index.php/RelateAdmix#Download>

RFMix: <https://sites.google.com/site/rfmixlocalancestryinference/>

GERMLINE: <http://www.cs.columbia.edu/~gusev/germline/>

DASH: <http://www1.cs.columbia.edu/~gusev/dash/>

PyMol: [www.pymol.org](http://www.pymol.org)

IBDNe: <http://faculty.washington.edu/browning/ibdne.html>
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Reviewing Editor
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United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Genetic Identification of a Common Collagen Disease in Puerto Ricans via Identity-by-Descent Mapping in a Health System\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mark McCarthy as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision letter to help you prepare a revised submission.

Summary:

The *eLife* editorial team finds your submitted research paper of considerable interest: it provides an excellent example how a large and clinically well characterised cohort with special population history can provide improved power to find novel rare mutations and haplotypes linked to Mendelian syndromes. Furthermore, the presented analytical strategy improves our understanding of already reported pathogenic mutations by efficiently increasing the number of variant carriers and finessing the resulting clinical picture.

The various contributors to the *eLife* Editorial team (reviewers, Reviewing Editor, Senior Editor) have raised some questions about aspects of the statistical and methodological approaches, and identified some weaknesses in the methods description, reported sample sizes and in referencing to tables and figures. Furthermore, we felt that some aspects of the work, like IBD detection, need to be explained more effectively to non-expert *eLife* readers.

Below, we provide a condensed list of Essential Revision actions that we consider need to be addressed in any revised submission.

Essential revisions:

1\) Aspects around IBD -- Please provide a more thorough description on the IBD methodology used. We\'d recommend starting with a more general description of IBD and its role in causal mutation detection -- currently the text is drafted in a manner that almost assumes the reader is very familiar with IBD analysis. Please explain specific terms, like \"local ancestry\".

Second, please justify the use of 3cM in IBD mapping. Third, provide more details in \"Materials and methods\" on how IBD cliques were identified and QCd.

2\) Aspects around Statistical Methods -- Currently, the manuscript lacks clarity on exactly which statistical models were applied to the data.

First, be specific about the regression models referred to in paragraph two of subsection "Detecting a Locus Shared Identical-by-Descent Underlying Extreme Short Stature in 172 Puerto Ricans" -- have you modelled the zscore as a function of the number of copies (0, 1, or 2) of the haplotype in a specific clique?

Second, the initial analysis of cliques relied on permutation to evaluate significance. Then when restricting analysis to Puerto Rican ancestry subjects (paragraph three of subsection "Detecting a Locus Shared Identical-by-Descent Underlying Extreme Short Stature in 172 Puerto Ricans") and 480 cliques w/ at least 3 people, are you using significance evaluated from asymptotics? Why the change in methodology? Bonferroni thresholds are mentioned, correcting for how many tests?

Third, the analysis of ICD9 codes vs. genotype at COL27A1.pG697R -- we assume you did 416 different logistic regressions, coding each subject as yes/no for a particular ICD9 diagnosis -- this could be made more clear. Was any correction done here for 416 tests? While the significance values are impressive, we concerned about inflation due to case-control imbalance.

Fourth, please repeat ICD9 codes vs. genotype at COL27A1.pG697R association testing using Firth test. It appears that many of these dx categories are quite rare, as is the variant. Logistic regression with case-control imbalance results in serious inflation of test statistics, particularly in the case of rare variants (see Ma et al., 2013 Genetic Epidemiology).

3\) Power of IBD mapping -- First, currently no power calculations are presented to substantiate the claim that the IBD mapping approach outperforms GWAS in terms of power. Please present these calculations as the p-value yielded through 10,000 permutations is only p=0.0018, which is substantially less than a GWAS significance threshold. Second, please clarify if the COL27A1.pG697R variant is imputable with 1000 Genomes reference. In the Materials and methods section, you provide detailed description on imputation. Furthermore in paragraph two of subsection "Fine-mapping Short Stature Locus Reveals Putative Link to Mendelian Syndrome" it states that there was 96.7% concordance between variant genotype and the associated haplotype -- so wouldn\'t the GWAS have identified the association using the variant?

4\) Genetic ancestry and COL27A1.pG697R variant -- Currently the text is lacking detailed description of the pathogenic variant. Furthermore, more detail is essential to understand how partitioning into ancestry groups was performed.

First, in the functional analysis section (subsection "Functional Investigation of COL27A1.pG697R"). Is the variant predicted damaging by popular annotation tools?- polyphen, sift, cadd, gerp, mutation taster, phyloP etc.

Second, please provide a confidence interval for the dating of the variant, (around 36 generations).

Third, please provide exact criteria how ancestry groups were defined from PCA vectors. Such details are currently missing from the Materials and methods. Furthermore, please provide clear evidence that suggest the populations that are described in subsection "Local Ancestry Estimation" present Native American are not admixed for European ancestry, or at least not significantly so.

10.7554/eLife.25060.033

Author response

> 1\) Aspects around IBD -- Please provide a more thorough description on the IBD methodology used. We\'d recommend starting with a more general description of IBD and its role in causal mutation detection -- currently the text is drafted in a manner that almost assumes the reader is very familiar with IBD analysis. Please explain specific terms, like \"local ancestry\".
>
> Second, please justify the use of 3cM in IBD mapping. Third, provide more details in \"Materials and methods\" on how IBD cliques were identified and QCd.

We have updated the text in several ways to address these points. We added a description of IBD mapping to the Introduction, Results, including references to previously published IBD mapping papers, Discussion, and Materials and methods. We have also added a supplemental figure schematic outlining the IBD mapping pipeline ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), referenced in the Results section. We have added explanation and background for the term local ancestry in several places throughout the text including Results and Materials and methods sections. We have added an explanation to justify the 3cM minimum used in IBD in the Results, including references that address this issue. Finally, we provide more details on how IBD cliques were identified and QC'd in Materials and methods, and [Figure 2---figure supplement 6](#fig2s6){ref-type="fig"} and [7](#fig2s7){ref-type="fig"}.

> 2\) Aspects around Statistical Methods -- Currently, the manuscript lacks clarity on exactly which statistical models were applied to the data.
>
> First, be specific about the regression models referred to in paragraph two of subsection "Detecting a Locus Shared Identical-by-Descent Underlying Extreme Short Stature in 172 Puerto Ricans" -- have you modelled the zscore as a function of the number of copies (0, 1, or 2) of the haplotype in a specific clique?
>
> Second, the initial analysis of cliques relied on permutation to evaluate significance. Then when restricting analysis to Puerto Rican ancestry subjects (paragraph three of subsection "Detecting a Locus Shared Identical-by-Descent Underlying Extreme Short Stature in 172 Puerto Ricans") and 480 cliques w/ at least 3 people, are you using significance evaluated from asymptotics? Why the change in methodology? Bonferroni thresholds are mentioned, correcting for how many tests?
>
> Third, the analysis of ICD9 codes vs. genotype at COL27A1.pG697R -- we assume you did 416 different logistic regressions, coding each subject as yes/no for a particular ICD9 diagnosis -- this could be made more clear. Was any correction done here for 416 tests? While the significance values are impressive, we concerned about inflation due to case-control imbalance.
>
> Fourth, please repeat ICD9 codes vs. genotype at COL27A1.pG697R association testing using Firth test. It appears that many of these dx categories are quite rare, as is the variant. Logistic regression with case-control imbalance results in serious inflation of test statistics, particularly in the case of rare variants (see Ma et al., 2013 Genetic Epidemiology).

We have revised the text substantially to update and clarify the details of the analysis, removed discussion of the additive IBD analysis as it does not add substantially to the our findings, and reordered the presentation of the analysis steps for better comprehension. To address the first point, we have explicitly described how we modeled the z scores in the Materials and method section. For the second point, we defined the Bonferonni adjustment in the Results and report Bonferonni adjusted genome-wide significance. To address the third point, we have clarified the description of the PheWAS analysis in the Results and Material and methods sections.

Regarding the fourth and fifth point, we agree with the reviewers general concern, however best practices for PheWAS models that jointly account for case:control imbalance, rare variants/ICD9 codes, and elevated distant relatedness remain an open problem for the genomics community. At the reviewers suggestion, and to examine this question, in addition to running an Generalized Linear Model (GLM), we ran three other score based tests; the Firth test that incorporates a bias-reduction for small numbers of observations (Ma et al., Genetic Epi 2013); a linear mixed model (GCTA) to account for distant relatedness (Yang et al., 2011); and a test that uses saddlepoint approximation (SPATest) to account for case:control imbalance (Dey et al., 2017). GLM and Firth test are each well vetted methods for case:control association, and GLMs are extensively used in PheWAS analysis. We also ran GCTA in binary trait mode and SPATest, which the author have kindly made available for download pre-publication. We added age, sex and the first five PC eigenvectors as covariates to each model. As anticipated, we observed over inflation in the distribution of the PheWAS test statistic, measured by λ (λ), for all four score based models (λGLM=1.59; λSPATest=1.20; λGCTA=1.36; λFirth=2.09), indicating that none of these models is perfectly calibrated. The top signal we originally reported, the ICD9 code linked to vertebral osteomyelitis (730.08), was the top signal in all four models. The other two signals, cervical spondylosis (721.0) and knee arthropathy (716.98) were each highly ranked, but only significantly in two of the four models. Therefore, to investigate whether there was support for the PheWAS findings, we extended the manual analysis of patient medical records, representing hundreds of hours of manual clinical chart review by two independent clinical experts. Information from inpatient, outpatient, emergency and private practice settings housed in the Mount Sinai health system since 2004 was reviewed. This data includes laboratory reports, radiological data, pathology results, operative notes and discharge summaries, pharmacy, inpatient results reviews, and nurses reports. The clinical experts examined for clinical features similar to those reported for Steel syndrome cases in Flynn et al., 2010, including developmental dysplasia of the hip (or congenital hip dysplasia), carpal coalition, scoliosis, and joint and spine anomalies. Both clinical experts reviewed patient records independently and compared notes to resolve discrepancies. They reviewed the records of the 34 youngest COL27A1.pG697R carriers (mean age 42), and compared their findings to 31 randomly selected age and sex matched Puerto Rican non-carriers, and also to published reports of population prevalences of key clinical features for similar age groups where available. In general they found increased incidence of strong to moderate spine and joint degradation in carriers compare to noncarriers (p\<0.03). Specifically, they found evidence of a significant incidence of cervical stenosis in carriers 5/34 carriers compared to 0/31 non-carriers (Fisher exact test p\<0.05). This was especially interesting as cervical stenosis, or narrowing of the upper spinal canal, is thought to be rare in individuals under the age of 50. Although not reaching statistically significance, they also found a trend of 2-fold higher rates of scoliosis (24%; p\<0.35), arthritis (38%; p\<0.1), and lumbar spine degradation (29%; p\<0.25) in carriers compared to non-carriers and previous published reports. We report the new analysis of the detailed chart review and additional PheWAS models in the Results, Discussion, [Table 1](#table1){ref-type="table"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and Materials and methods.

> 3\) Power of IBD mapping -- First, currently no power calculations are presented to substantiate the claim that the IBD mapping approach outperforms GWAS in terms of power. Please present these calculations as the p-value yielded through 10,000 permutations is only p=0.0018, which is substantially less than a GWAS significance threshold. Second, please clarify if the COL27A1.pG697R variant is imputable with 1000 Genomes reference. In the Materials and methods section, you provide detailed description on imputation. Furthermore in paragraph two of subsection "Fine-mapping Short Stature Locus Reveals Putative Link to Mendelian Syndrome" it states that there was 96.7% concordance between variant genotype and the associated haplotype -- so wouldn\'t the GWAS have identified the association using the variant?

The specific issue here is that IBD tagged the three true homozygotes perfectly, whereas a standard imputation pipeline (SHAPEIT2/IMPUTE2/1000 Genomes Project phase 3 reference panel) called one of the homozygotes as a heterozygote. Running the same recessive model in both cases results in an difference of the p-value of association from p\<2.57x10-11 (number of homozygotes=3; IBD-clique frequency=0.012; β=- 3.78; rank=1) to p\<0.001 (number of homozygotes=2; MAF=0.014: β=-3.0; rank=11775) comparing IBD mapping with SNP imputation, respectively. In addition, there were over 10 million SNP tests performed in the imputed dataset compared to the 480 IBD-cliques tested in the IBD mapping approach, so the Bonferonni adjusted genome-wide significance testing burden is considerably reduced in the IBD mapping approach. Despite the frequencies and effects sizes being similar for both approaches, the p-values and absolute rank of the test of association are diminished for the imputation approach. Thus, in this case, IBD mapping was better powered compared to the SNP imputation approach for association of the recessive COL27A1.pG697R allele. Recent methods that leverage IBD for imputation, such as EAGLE (Loh et al.,Nat Genet 2016), have demonstrated improved accuracy of low frequency and rare variant imputation and may have improved imputation of the homozygotes in this study. However, the broader point is that imputation methods are dependent on representative haplotypic diversity in the sequence reference panels. Since rare disease variants are more likely to be population-specific or geographically localized, lacking the relevant diversity in sequence reference panels or sequence discovery efforts means that inference of rare variants within cohorts independent of available reference panels via methods like IBD mapping, which rely on inferring distant familial relationships, are likely to remain important for disease variant discovery.

We have updated the text to clarify details of this analysis in subsection "Fine-mapping Short Stature Locus Reveals Putative Link to Mendelian Syndrome", [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}, [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

> 4\) Genetic ancestry and COL27A1.pG697R variant -- Currently the text is lacking detailed description of the pathogenic variant. Furthermore, more detail is essential to understand how partitioning into ancestry groups was performed.
>
> First, in the functional analysis section (subsection "Functional Investigation of COL27A1.pG697R"). Is the variant predicted damaging by popular annotation tools?- polyphen, sift, cadd, gerp, mutation taster, phyloP etc.
>
> Second, please provide a confidence interval for the dating of the variant, (around 36 generations).
>
> Third, please provide exact criteria how ancestry groups were defined from PCA vectors. Such details are currently missing from the Materials and methods. Furthermore, please provide clear evidence that suggest the populations that are described in subsection "Local Ancestry Estimation" present Native American are not admixed for European ancestry, or at least not significantly so.

We have added details to the text to clarify the first and third points in the Results and Materials and methods sections, [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. For the second point, we cannot provide a confidence interval as the estimate was based on two heterozygote observations (in the 100 sequenced Puerto Rican's in the 1000 Genomes Project). Since we have no way to infer the stability of the estimate, we removed this analysis from the paper. Instead we add a new analysis to estimate the timing and magnitude of the putative founder event in Puerto Rico by demographic modeling using the tract length distribution of IBD tracts in contemporary Puerto Rican populations with IBDNe (Browning and Browning, Am J Hum Genet 2015). We estimate a strong bottleneck in Puerto Rico dating approximately 12 generations ago (estimated effective population size=2580, 95% C.I 2320-2910). This is described in the Results, Discussion and Materials and methods sections, and [Figure 4C](#fig4){ref-type="fig"}.
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